December 21, 2022
2 minute clock
Al Hadidi does not report related financial disclosures.
New Orleans — In this video’s perspective, Samer Al-Hadidi, MD, MS, FACP, A presentation from the ASH Annual Meeting and Exposition focused on therapies that have resulted in better tolerance for patients with multiple myeloma.
A randomized phase III trial found that initial steroid-free treatment was comparable to steroid-containing regimens in frail elderly multiple myeloma patients, said Al Hadidi, an associate professor at the Arkansas College of Medicine and Science. I thought
“This is important in trying to tailor treatments to patients,” he told Healio.
A separate presentation of a randomized trial found that an unrestricted diet did not appear to increase infection rates after hematopoietic stem cell transplantation and was associated with improved patient satisfaction, Al Hadidi said. rice field.
- Manier S et al. Abstract 569. Place of presentation: ASH Annual Meetings and Expositions. December 10-13, 2022. New Orleans.
- Stella F. et al Abstract 169. Place of presentation: ASH Annual Meetings and Expositions. December 10-13, 2022. New Orleans.